They raised guidance and admitted price increases are only 'almost insignificant' to Q3 numbers. The real ASP story is 2027.
Thesis: TI owns the bottleneck removal. While competitors quote 52-week lead times, TI has clean room space at Sherman and Lehigh shells ready to equip. Every line-down rescue at 13-week lead times converts to design wins that compound for years. Pricing just started rolling, customer by customer, and management said 2026 unit growth alone drives Q3 guide. The market is modeling a normal analog cycle with 2-3 point annual price declines. TI is raising prices. That is the edge.
Verdict: LONG — Conviction: MEDIUM
Catalyst: Q3 earnings showing gross margin expansion beyond the guide midpoint, confirming price increases flow through while volume grows. CEO's 2027/2028 capacity decisions translate into capex above the $3B top of range.
Key Risk: FCF framework of $9-10B at $22B revenue depends on ITC subsidies that reverse as capex shifts disproportionately to offshore assembly/test. Organic FCF of $4.9B covers only 85% of the $5.8B returned to shareholders.
The Tell: CEO volunteered that Q3 pricing contribution is 'almost insignificant' despite the pricing power narrative. He said: 'the vast majority of it is just unit growth and maybe a little contribution from pricing.' Management is managing expectations on near-term ASP benefit while the street may be underwriting immediate pricing impact. The real pricing leverage lands in 2027, not Q3.
Friction Level: MODERATE_FRICTION — Both sides agree demand is broad and pricing power is emerging. The disagreement is whether the $6.5B TTM FCF is real or inflated by $1.6B of CHIPS Act subsidies that reverse as capex shifts to offshore assembly/test with zero ITC benefit.
Report not found
The report data is no longer available. Please return to the archive.